Literature DB >> 15725082

Low-grade primary central nervous system lymphoma in immunocompetent patients.

Kristoph Jahnke1, Eckhard Thiel, Andreas Schilling, Ulrich Herrlinger, Michael Weller, Sarah E Coupland, Ulrich Krümpelmann, Harald Stein, Agnieszka Korfel.   

Abstract

Primary central nervous system lymphomas (PCNSL) are usually diffuse large B-cell non-Hodgkin's lymphomas (NHL). Here we characterize the clinical presentation, course and outcome of patients with low-grade PCNSL. Records of 332 patients screened for inclusion in three multicentre prospective trials were reviewed. Ten patients (3%) with a median age of 59 years and a median Karnofsky performance status of 70% were identified. Seven patients had B-cell and three had T-cell lymphoma. The median growth fraction was 4%. The radiological morphology was unusual for PCNSL in eight patients. Three patients underwent complete tumour resection, combined with chemotherapy in one patient and with chemotherapy plus local radiotherapy in another. Four patients received chemotherapy and three received chemotherapy plus whole-brain irradiation, resulting in four complete remissions, two no-change situations and one progressive disease. Patients had an overall survival (OAS) of 2-58+ months with a 2-year OAS of 67%. Low-grade PCNSL may differ from classical high-grade PCNSL in its clinical features and radiological morphology. The clinical course may be variable and frequently more indolent than in classical PCNSL.

Entities:  

Mesh:

Year:  2005        PMID: 15725082     DOI: 10.1111/j.1365-2141.2004.05361.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Primary CNS T-cell Lymphomas: A Clinical, Morphologic, Immunophenotypic, and Molecular Analysis.

Authors:  Madhu P Menon; Alina Nicolae; Hillary Meeker; Mark Raffeld; Liqiang Xi; Armin G Jegalian; Douglas C Miller; Stefania Pittaluga; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2015-12       Impact factor: 6.394

2.  Primary CNS lymphoma.

Authors:  Uwe Schlegel
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

3.  Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma.

Authors:  Roy E Strowd; Inas A Abuali; Stuart A Grossman
Journal:  CNS Oncol       Date:  2015-04-23

4.  High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma.

Authors:  Philipp Kiewe; Christoph Loddenkemper; Ioannis Anagnostopoulos; Mark Reinwald; Eckhard Thiel; Agnieszka Korfel
Journal:  Neuro Oncol       Date:  2007-02-14       Impact factor: 12.300

5.  Primary central nervous system lymphoma.

Authors:  Hendrik Pels; Uwe Schlegel
Journal:  Curr Treat Options Neurol       Date:  2006-07       Impact factor: 3.972

6.  Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia.

Authors:  Julie Catusse; Marion Leick; Mareike Groch; David J Clark; Maike V Buchner; Katja Zirlik; Meike Burger
Journal:  Mol Cancer       Date:  2010-11-22       Impact factor: 27.401

7.  B cell-rich non-neoplastic sentinel lesion preceding primary central nervous system lymphoma.

Authors:  Rodrigo Javier; Nawal Shaikh; Maciej S Lesniak; Adam Sonabend; Roger Stupp; Amir Behdad; Craig Horbinski
Journal:  Diagn Pathol       Date:  2018-06-05       Impact factor: 2.644

8.  Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma.

Authors:  Defeng Zhao; Liren Qian; Jianliang Shen; Xiaopeng Liu; Ke Mei; Jian Cen; Yaming Wang; Congyong Li; Yuanyuan Ma
Journal:  J Cell Mol Med       Date:  2014-03-13       Impact factor: 5.310

9.  Primary cerebral low-grade B-cell lymphoma, monoclonal immunoglobulin deposition disease, cerebral light chain deposition disease and "aggregoma": an update on classification and diagnosis.

Authors:  Marco Skardelly; Georgios Pantazis; Sotirios Bisdas; Guenther C Feigl; Martin U Schuhmann; Marcos S Tatagiba; Rainer Ritz
Journal:  BMC Neurol       Date:  2013-08-15       Impact factor: 2.474

10.  Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.

Authors:  Liren Qian; Chunhui Zhou; Jianliang Shen; Jian Cen; Wenjie Yin
Journal:  Oncotarget       Date:  2016-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.